Sarah Acaster, Clara Mukuria, Donna Rowen, John E Brazier, Claire E Wainwright, Bradley S Quon, Jamie Duckers, Alexandra L Quittner, Yiyue Lou, Patrick Sosnay, Lisa J McGarry
OBJECTIVE: Cystic fibrosis (CF) limits survival and negatively affects health-related quality of life (HRQOL). Cost-effectiveness analysis (CEA) may be used to make reimbursement decisions for new CF treatments; however, generic utility measures used in CEA, such as EQ-5D, are insensitive to meaningful changes in lung function and HRQOL in CF. Here we develop a new, CF disease-specific, preference-based utility measure based on the adolescent/adult version of the Cystic Fibrosis Questionnaire-Revised (CFQ-R), a widely used, CF-specific, patient-reported measure of HRQOL...
December 9, 2022: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research